Scientists have said that an enzyme, called human polynucleotide phosphorylase or hPNPaseold-35 could play a major role in preventing melanoma-the most serious type of skin cancer.
Scientists at Virginia Commonwealth University have discovered a mechanism by which the enzyme regulates gene expression and growth in melanoma cells-a finding that could one day lead to more effective drugs to attack cancers and make them more treatable.
Advertisement
The study suggests that hPNPaseold-35 might be used to target a specific genetic component that helps to regulate gene expression and defends melanoma cells against treatment.
"By selectively and specifically targeting molecules for degradation that serve as gatekeepers for cancer growth, progression and resistance to therapy, it may be possible to turn the cancer cells' defense into an offense that can be used as an effective approach to destroy the tumor," said Dr. Paul B. Fisher.
![Skin Disease]( "Skin Disease")
Skin diseases also known as dermatologic disorders are many in number and so are their causes. The common skin diseases or skin disorders are usually related to the epidermal layer of skin.
Several years ago, Fisher led a team of scientists at Columbia University in identifying an enzyme involved in halting the growth of human malignant melanoma and other cancer cells.
The enzyme, called human polynucleotide phosphorylase or hPNPaseold-35, drives cancerous cells to irreversibly lose their growth potential and acquire properties of more normal cells, a process called terminal cell differentiation.
The enzyme also is important in cellular senescence, when a cell cannot divide anymore and dies.
In addition, the investigators developed new strategies for promoting cancer cell-specific expression of this enzyme, which reduced tumour growth in animal cancer models.
Now, Fisher and VCU colleagues report that hPNPaseold-35 selectively targets and degrades a genetic component known as microRNA-221.
MicroRNAs are short genetic components that act like a volume control knob to regulate the production of defined proteins in cells.
MicroRNAs regulate the expression of more than a third of human genes.
In recent years, they have been recognized as causing over- or under-expression of genes linked to the majority of cancers and other diseases.
Researchers are exploring microRNAs' roles to understand how they could be used as potential targets for therapies.
The study indicates that showering the cell with the hPNPaseold-35 enzyme preferentially degrades microRNA-221, a microRNA that is elevated in multiple cancers including melanoma and which regulates gene expression that promotes the cancer cells' ability to thrive and spread. MicroRNA-221 also endows melanoma and other cancers with the capacity to resist chemotherapy.
"The present study provides the first observation that microRNAs may be regulated by selective degradation, providing an entry point for developing novel approaches for the therapy of melanoma and other cancers," said Fisher.
The study also found that interferon-beta, a treatment for melanoma and other cancers, induces cells to produce the enzyme while also interfering with the ability of microRNA-221 to perform. Fisher said this provides one possible explanation for how interferon-beta suppresses growth of melanoma cells.
The findings are reported in the Proceedings of the National Academy of Sciences.
Source: ANI
Skin Disease
Skin diseases also known as dermatologic disorders are many in number and so are their causes. The common skin diseases or skin disorders are usually related to the epidermal layer of skin.
Advertisement
Several years ago, Fisher led a team of scientists at Columbia University in identifying an enzyme involved in halting the growth of human malignant melanoma and other cancer cells.
The enzyme, called human polynucleotide phosphorylase or hPNPaseold-35, drives cancerous cells to irreversibly lose their growth potential and acquire properties of more normal cells, a process called terminal cell differentiation.
The enzyme also is important in cellular senescence, when a cell cannot divide anymore and dies.
In addition, the investigators developed new strategies for promoting cancer cell-specific expression of this enzyme, which reduced tumour growth in animal cancer models.
Now, Fisher and VCU colleagues report that hPNPaseold-35 selectively targets and degrades a genetic component known as microRNA-221.
MicroRNAs are short genetic components that act like a volume control knob to regulate the production of defined proteins in cells.
MicroRNAs regulate the expression of more than a third of human genes.
In recent years, they have been recognized as causing over- or under-expression of genes linked to the majority of cancers and other diseases.
Researchers are exploring microRNAs' roles to understand how they could be used as potential targets for therapies.
The study indicates that showering the cell with the hPNPaseold-35 enzyme preferentially degrades microRNA-221, a microRNA that is elevated in multiple cancers including melanoma and which regulates gene expression that promotes the cancer cells' ability to thrive and spread. MicroRNA-221 also endows melanoma and other cancers with the capacity to resist chemotherapy.
"The present study provides the first observation that microRNAs may be regulated by selective degradation, providing an entry point for developing novel approaches for the therapy of melanoma and other cancers," said Fisher.
The study also found that interferon-beta, a treatment for melanoma and other cancers, induces cells to produce the enzyme while also interfering with the ability of microRNA-221 to perform. Fisher said this provides one possible explanation for how interferon-beta suppresses growth of melanoma cells.
The findings are reported in the Proceedings of the National Academy of Sciences.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
A ray of hope for glioma patients as targeted therapy boosts treatment duration.
In patients with breast cancer combination therapy had increased invasive disease-free survival compared to those who were treated with the hormone therapy alone.
An antibody treatment helped shrink tumors in some patients with bile duct cancers.